Q-omics provides the consensus-scored RTRAFP1 profile across patient tissues and cancer cell-line models. RTRAFP1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, RTRAFP1 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, RTRAFP1 RNA expression shows 9,700 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight CHOL, COAD, and BRCA as cancer lineages where RTRAFP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RTRAFP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RTRAFP1 survival associations across molecular data types. RTRAFP1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RTRAFP1 RNA expression–survival associations across cancer types. High RTRAFP1 expression shows unfavorable associations in CHOL, STAD, KICH and BLCA, but favorable associations in SKCM and COAD. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify CHOL as the clearest survival context for RTRAFP1 RNA expression.
This table summarizes RTRAFP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RTRAFP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RTRAFP1 shows higher tumor expression in COAD, LIHC, THCA, PRAD, LUSC and LUAD. The COAD box plot shows higher RTRAFP1 RNA expression in tumor versus normal tissue (log2 FC = +0.224, t-test p = .004).
This table shows molecular features associated with RTRAFP1 in patient tissues and cancer cell lines. In patient samples, RTRAFP1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
